CollabRx and The Nicholas Conor Institute are excited to announce a partnership to apply CollabRx’s personalized research approach to childhood cancers. As part of this partnership, patients will receive personalized therapy based upon the best available science, and researchers will continuously test and refine their models of childhood cancer biology and therapeutics based on the resulting clinical responses.

The Melanoma Research Alliance supports ambitious and innovative projects from both individual scientists and research teams to develop novel diagnostic and therapeutic avenues relevant to pathways governing the behavior and clinical outcome of melanoma.

Science Commons' mission is to speed the translation of basic research to useful discoveries. CollabRx has partnered with Science Commons, the Public Library of Science (PLoS), and CommerceNet to form Health Commons. Health Commons aims at bringing the same efficiencies to human health that the network brought to commerce. An introduction and overview is provided in the white paper, Health Commons: Therapy Development in a Networked World , co-authored by Marty Tenenbaum, Chairman and Chief Scientist at CollabRx, and John Wilbanks, Vice President of Science at Creative Commons.

FasterCures is dedicated to saving lives by saving time. Their mission is to identify and implement global solutions to accelerate the process of discovery and clinical development of new therapies for the treatment of deadly and debilitating diseases.

Public Library of Science (PLoS) is a nonprofit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. CollabRx is partnering with PLoS, Science Commons, and CommerceNet on the Health Commons initiative which aims to change the way basic science is translated into the understanding and improvement of human health.